Dual incretin agonist (revision 10)

A dual incretin agonist is a single engineered peptide that activates two receptors of the glucagon-secretin family — most often the receptor for Glucose-dependent insulinotropic polypeptide and the GLP-1 receptor — in a ratio fixed by its chemistry rather than by a prescriber's choice of two drugs.^[1]

The approach differs fundamentally from co-administration of two agents. A single molecule delivers both activities to the same tissues with identical pharmacokinetics, so the ratio at the receptor does not drift with differential clearance. The price is that the ratio cannot be adjusted: it is a property of the molecule, and changing it means changing the drug.^[2]

Tirzepatide is the only member marketed to date. Why dual agonism outperforms GLP-1 monotherapy is not settled, and the leading explanations — adipose-tissue GIP action, central GIP effects that improve tolerability, and restoration of beta-cell GIP responsiveness under ambient GLP-1 signalling — have not been separated by any published trial.^[3]

The receptors of this family share a common architecture — a large extracellular domain capturing the C-terminal helix of the ligand, and a transmembrane bundle engaged by the ligand N-terminus — and roughly 40–50% sequence identity in the transmembrane region. That relatedness is what makes a single ligand for two of them possible.^[1]

The design proceeds by choosing a backbone, then substituting residues that confer activity at the second receptor while retaining activity at the first. In practice a GIP backbone has proved more tolerant of the substitutions needed for GLP-1 activity than the reverse, which is why tirzepatide is built from GIP rather than from GLP-1.^[2]

Reported potency ratios are assay-dependent — cell line, readout, incubation time and receptor expression level all move them — and cross-publication comparison of ratios is unreliable. A ratio quoted without its assay system is not a meaningful number.